This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Benimetskaya, L. Articles by Stein, C. A. Search for Related Content PubMed PubMed Citation Articles by Benimetskaya, L. Articles by Stein, C. A.

Relative Bcl-2 Independence of Drug-Induced Cytotoxicity and Resistance in 518A2 Melanoma Cells

¹ Albert Einstein-Montefiore Cancer Center, Department of Oncology, Montefiore Medical Center, Bronx, New York; ² Department of Biomedical Engineering, Columbia University, New York, New York; ³ Dharmacon Research, Lafayette, Colorado; and ⁴ Johns Hopkins University, School of Public Health, Baltimore, Maryland

Purpose: Inhibition of the function of Bcl-2 protein has been postulated to sensitize cells to cytotoxic chemotherapy. G3139 (Genasense) is a phosphorothioate anti–Bcl-2 antisense oligonucleotide, but its mechanism of action is uncertain. The aim of the present work is to investigate inhibition of Bcl-2 expression in 518A2 melanoma cells, the cell line on which recent phase II and phase III clinical trials employing this agent were based.

Experimental Design: We down-regulated the expression of Bcl-2 protein by two different strategies in these cells: one employing G3139 and controls, and the other using a small interfering RNA approach. Cell viability after treatment with oligonucleotides or small interfering RNA and cytotoxic agents including gemcitibine, DDP, docetaxel, and thapsigargin was measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. A 518A2 melanoma cell line stably overexpressing Bcl-2 protein was constructed and treated with either these cytotoxic agents or G3139.

Results: The cytotoxic effects of either G3139 or small interfering RNA treatment of 518A2 melanoma cells are Bcl-2 independent. In addition, in the Bcl-2–overexpressing cells, only a modest increment in chemoresistance was observed, and treatment with G3139 not only did not down-regulate Bcl-2 expression but produced essentially identical toxicity as was observed in the wild-type or mock-transfected cells.

Conclusions: Our results suggest that the mechanism whereby G3139 produces drug-induced cytotoxicity in the 518A2 melanoma line is not dependent on levels of Bcl-2. These findings emphasize the nonsequence specific effects of this phosphorothioate oligonucleotide and call into question the validity of Bcl-2 as a target in this cell line.

This article has been cited by other articles:

				V. Lamy, S. Roussi, M. Chaabi, F. Gosse, N. Schall, A. Lobstein, and F. Raul Chemopreventive effects of lupulone, a hop {beta}-acid, on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis Carcinogenesis, July 1, 2007; 28(7): 1575 - 1581. [Abstract] [Full Text] [PDF]

				L. Benimetskaya, K. Ayyanar, N. Kornblum, D. Castanotto, J. Rossi, S. Wu, J. Lai, B. D. Brown, N. Popova, P. Miller, et al. Bcl-2 Protein in 518A2 Melanoma Cells In vivo and In vitro. Clin. Cancer Res., August 15, 2006; 12(16): 4940 - 4948. [Abstract] [Full Text] [PDF]

				J. C. Lai, W. Tan, L. Benimetskaya, P. Miller, M. Colombini, and C. A. Stein A pharmacologic target of G3139 in melanoma cells may be the mitochondrial VDAC PNAS, May 9, 2006; 103(19): 7494 - 7499. [Abstract] [Full Text] [PDF]

				J. C. Lai, L. Benimetskaya, A. Khvorova, S. Wu, E. Hua, P. Miller, and C.A. Stein Phosphorothioate oligodeoxynucleotides and G3139 induce apoptosis in 518A2 melanoma cells Mol. Cancer Ther., February 1, 2005; 4(2): 305 - 315. [Abstract] [Full Text] [PDF]